|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
09939 KINTOR PHARMA-B
Nominal 
2.240 -0.040 (-1.754%) | 2025/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Turnover | 5,984 | -- | 5,000 | 0 | 0 | 34,231 |
| Cost of Sales | (6,180) | -- | (9,730) | (42,229) | -- | -- |
| Gross Profit | (196) | -- | (4,730) | (42,229) | -- | -- |
| 2025/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | (1,206) | -- | -- | -- | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | (481) | -- | (1,429) | 52 | (568) | 0 | |
| Profit / (Loss) before Taxation | (83,545) | 16.887% | (155,274) | (1,068,861) | (953,284) | (842,095) | |
| Taxation | 277 | -- | (18) | 8,041 | (1,085) | 0 | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 0 | -- | 0 | 0 | 0 | 0 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | (83,268) | 16.470% | (155,292) | (1,060,820) | (954,369) | (842,095) | |
| 2025/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Net Finance Costs / (Income) | 2,236 | -57.124% | 5,068 | (3,387) | 1,305 | (9,555) |
| Depreciation & Amortisation | 12,658 | 45.394% | 17,627 | 18,976 | 18,388 | 10,510 |
| Directors' Emoluments | -- | -- | 10,422 | 27,362 | 18,573 | 6,570 |
| 2025/06 - Interim | %Chg (Compare to Interim) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| Auditor's Opinion Status | N/A | -- | Unqualified (Modified Report) | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2025/06 - Interim | %Chg (Compare to Interim) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| EPS (cts) | -19.000 | 11.765% | -36.000 | -247.000 | -253.000 | -236.000 |
| DPS (cts) | 0.000 | -- | 0.000 | 0.000 | 0.000 | 0.000 |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | -- |
| Cash flow per share ($) | -- | -- | (0.462) | (0.903) | (2.553) | (2.950) |
| NBV per share ($) | 0.483 | -- | 0.657 | 1.024 | 3.341 | 4.270 |
| Remarks: | Real time quote last updated: 11/09/2025 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB -83,268 |
| %Change | 16.470% |
| EPS / (LPS) | RMB -0.190 |
| NBV Per Share (¥) | RMB 0.483 |